Provided by Tiger Fintech (Singapore) Pte. Ltd.

ImmunityBio, Inc.

2.52
-0.0550-2.14%
Volume:6.86M
Turnover:17.41M
Market Cap:2.38B
PE:-5.14
High:2.58
Open:2.56
Low:2.49
Close:2.57
52wk High:7.48
52wk Low:1.83
Shares:945.25M
Float Shares:194.00M
Volume Ratio:0.80
T/O Rate:3.54%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4893
EPS(LYR):-0.5931
ROE:78.05%
ROA:-42.14%
PB:-4.17
PE(LYR):-4.24

Loading ...

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jun 03

ImmunityBio Inc. to Attend ASCO Annual Meeting 2025 in Chicago

Reuters
·
Jun 03

ImmunityBio Inc. Receives FDA Expanded Access Authorization for ANKTIVA Cancer BioShield™ to Treat Lymphopenia in Solid Tumor Patients

Reuters
·
Jun 02

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
May 28

ImmunityBio Raised to Overweight From Neutral by Piper Sandler

Dow Jones
·
May 20

Immunitybio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers Health, TXNM Energy, Forge Global

Reuters
·
May 13

ImmunityBio Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
May 13

BUZZ-ImmunityBio rises on Q1 revenue beat

Reuters
·
May 12

Sector Update: Health Care Stocks Advance Premarket Monday

MT Newswires Live
·
May 12

ImmunityBio Is Maintained at Buy by D. Boral Capital

Dow Jones
·
May 12

ImmunityBio Q1 Loss Narrows, Revenue Rises

MT Newswires Live
·
May 12

Earnings Flash (IBRX) ImmunityBio Posts Q1 Net Loss $0.15 a Share, vs. FactSet Est of $0.13 Loss

MT Newswires Live
·
May 12

ImmunityBio Q1 EPS $(0.15) Misses $(0.13) Estimate, Sales $16.52M Beat $16.02M Estimate

Benzinga
·
May 12

Press Release: ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code

Dow Jones
·
May 12

Immunitybio Inc expected to post a loss of 13 cents a share - Earnings Preview

Reuters
·
May 10

ImmunityBio Slides Following FDA Refusal-to-File Letter

Dow Jones
·
May 06

ImmunityBio Seeks Urgent FDA Meeting After Rejection for Bladder Cancer Therapy

MT Newswires Live
·
May 05

ImmunityBio Requests Meeting With FDA Over Rejected Bladder Treatment Application

Dow Jones
·
May 05

BRIEF-ImmunityBio Requests An Urgent Meeting With FDA To Address The Change In The Agency’S Unambiguous Guidance On Jan 2025 To Submit A SBLA For NMIBC BCG Unresponsive Papillary Disease, Following An Inconsistent Refusal To File Letter On May 2, 2025

Reuters
·
May 05